MSD has welcomed confirmation that its Keytruda (pembrolizumab) has become the first and only anti-PD-1 immunotherapy approved to treat head and neck cancer in Australia.
The TGA has approved the 200mg dose of Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma where disease progression has occurred on or after platinum-containing chemotherapy.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Mar 17
